<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00262639</url>
  </required_header>
  <id_info>
    <org_study_id>15844</org_study_id>
    <nct_id>NCT00262639</nct_id>
  </id_info>
  <brief_title>Prometa Protocol for Alcohol Dependence</brief_title>
  <official_title>A Double Blind Evaluation of Flumazenil and Gabapentin for the Treatment of Alcohol Withdrawal and Relapse Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a placebo controlled trial (some people receive active and some people receive
      inactive medication) to evaluate the effectiveness of a new protocol to treat alcohol
      dependence. Two main medications (plus ancillary non-placebo controlled medications) and
      their placebos (inactive drugs) will be utilized to treat both alcohol withdrawal, promote
      abstinence, and reduce drinking over approximately a six-week treatment period. All
      participants will meet criteria for Alcohol Dependence and be drinking heavily up until 72
      hours prior to receiving the first study drug. They will be injected one drug (flumazenil or
      placebo) over a two day period and receive the second one (gabapentin or placebo) by mouth
      for 39 days. The main hypothesis is that this protocol will reduce early alcohol withdrawal
      symptoms and will reduce relapse to drinking and promote abstinence compared to the placebo
      (inactive) drug group. Secondary outcomes that will be evaluated include reduction in
      craving, improvement in sleep, brain activity and mood.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 60 alcohol dependent individuals who are drinking heavily up until 72 hours, or
      less, prior to study participation will be randomized to receive either flumazenil
      (intravenously)on two successive days and gabapentin (orally)for 39 days or their matching
      placebos. They also will receive hydroxyzine and vitamins. Individuals will be evaluated for
      alcohol withdrawal, their response to acoustic startle, cognitive ability, craving, mood,
      sleep and drinking during the first week. They will then be seen weekly for about 6 weeks
      during which they take gabapentin or placebo and are provided with Combined Behavioral
      Intervention Therapy (counseling) once a week, or more, as required. Over this period they
      will be evaluated weekly for alcohol consumption, craving, sleep, mood, and biological
      markers of alcohol consumption ( percent carbohydrate deficient transferrin and
      gamma-glutamyl transferase). Blood will be obtained on week 3 and 6 for general health
      (liver, blood count etc.) screening. After the end of treatment, subjects will be followed-up
      at 4 weeks and again at 8 weeks after treatment to evaluate alcohol consumption, craving,
      sleep, mood.

      Subjects will undergo a functional magnetic resonance imaging (MRI) procedure sometime during
      the second or third week of study medication to assess cue induced regional brain activation
      to investigate the effect of medication on brain response to alcohol visual cues.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Subjects Completely Abstinent</measure>
    <time_frame>16 week trial</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Alcohol Withdrawal Scores (CIWAar)</measure>
    <time_frame>Day 1 Day 2 Week 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Days Abstinent</measure>
    <time_frame>Weeks 1 to 6, 10 and 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep</measure>
    <time_frame>Weeks 1 to 6, 10 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acoustic Startle Response</measure>
    <time_frame>Day 1, Day 3, Week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional Brain Activity on fMRI</measure>
    <time_frame>Week 2</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg flumazenil given over 20 minutes on Day 1 and Day 2. Gabapentin 300 mg Day 1; gabapentin 600 mg Day 2; gabapentin 900 mg Day 3; gabapentin 1200 mg Day 4 to 30; gabapentin 900 mg day 31-33; gabapentin 600 mg day 34-36; gabapentin 300 mg day 37-39.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flumazenil and Gabapentin</intervention_name>
    <description>2 mg flumazenil for infusion given slowly over 20 minutes given day 1 and day 2 gabapentin 300 mg increasing to 1200 mg over 4 days and continuing to day 30. Gabapentin 900 mg Day 31 to Day 33 gabapentin 600 mg Day 34 to 36 and gabapentin 300 mg Day 37 to 39.</description>
    <arm_group_label>I</arm_group_label>
    <arm_group_label>II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.</description>
    <arm_group_label>II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 - 70.

          2. Participants will meet criteria for primary DSM IV alcohol dependence, drink on at
             least 70% of days in the last 30 days prior to assessment, and drink at least 5 drinks
             per drinking day.

          3. No more than 72 hours since last drink of alcohol. Rationale: to focus on symptoms
             occurring during the early alcohol cessation period.

          4. Low CIWA-Ar group: have a CIWA-Ar score less than or equal to 6; High CIWA-Ar group:
             have a CIWA-Ar score greater than or equal to 7 but less than or equal to 15.

          5. Able to read and understand questionnaires and informed consent.

          6. Has stable housing for past 3 months.

        Exclusion Criteria:

          1. Currently meets DSM-IV criteria for any other psychoactive substance dependence
             disorder except nicotine dependence.

          2. Any psychoactive substance abuse, except marijuana and nicotine, within the last 30
             days as evidenced by subject report or urine drug screen.

          3. Meets DSM-IV criteria for current axis I disorders of major depression, panic
             disorder, obsessive-compulsive disorder, generalized anxiety disorder, post-traumatic
             stress syndrome, bipolar affective disorder, schizophrenia, or any other psychotic
             disorder or organic mental disorder. The rationale for excluding them is that symptoms
             from these disorders may affect dependent variables and complicate interpretation of
             the data.

          4. No use of benzodiazepines in excess of three times in the past two weeks by self
             report and urine drug screen.

          5. Subjects must not be taking zolpidem (Ambien™), zaleplon (Sonata™), or eszopiclone
             (Lunesta™) in excess of three times in past two weeks.

          6. No history of delirium tremens or alcohol withdrawal seizures.

          7. Has current suicidal ideation with plan or homicidal ideation.

          8. Need for maintenance or acute treatment with any psychoactive medication including
             antiseizure medications.

          9. Use of disulfiram, naltrexone, acamprosate, or anticonvulsants in last 30 days.

         10. Clinically significant medical problems such as cardiovascular, renal, GI, or
             endocrine problem that would impair participation or limit medication ingestion.

         11. Sexually active females of child-bearing potential who are pregnant (by -beta HCG),
             nursing, or who are not using a reliable form of birth control.

         12. Has current charges pending for a violent crime (not including DUI related offenses).

         13. Has taken gabapentin or flumazenil in the last month or has experienced adverse
             effects from it at any time in the past.

         14. Hepatocellular disease indicated by elevations of SGPT (ALT) and SGOT (AST) greater
             than 3 times normal at screening.

         15. Persons with metal implants or pacemaker since fMRI will be used.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond F Anton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MUSC-Center for Drug and Alcohol Programs</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.muschealth.com/cdap/</url>
    <description>Main Web Page for the MUSC-Center for Drug and Alcohol Programs</description>
  </link>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2005</study_first_submitted>
  <study_first_submitted_qc>December 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2005</study_first_posted>
  <results_first_submitted>July 6, 2009</results_first_submitted>
  <results_first_submitted_qc>July 6, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 14, 2009</results_first_posted>
  <last_update_submitted>December 9, 2009</last_update_submitted>
  <last_update_submitted_qc>December 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Raymond F. Anton, MD</name_title>
    <organization>Medical University of South Carolina</organization>
  </responsible_party>
  <keyword>Alcoholism</keyword>
  <keyword>Alcohol Dependence</keyword>
  <keyword>Alcohol Withdrawal</keyword>
  <keyword>Treatment</keyword>
  <keyword>Pharmacotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
    <mesh_term>Flumazenil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low CIWA Flumazenil/Gabapentin</title>
          <description>2 mg flumazenil given over 20 minutes on Day 1 and Day 2. Gabapentin 300 mg Day 1; gabapentin 600 mg Day 2; gabapentin 900 mg Day 3; gabapentin 1200 mg Day 4 to 30; gabapentin 900 mg day 31-33; gabapentin 600 mg day 34-36; gabapentin 300 mg day 37-39.</description>
        </group>
        <group group_id="P2">
          <title>Low CIWAar Placebo</title>
          <description>20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.</description>
        </group>
        <group group_id="P3">
          <title>High CIWAar Placebo</title>
          <description>20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.</description>
        </group>
        <group group_id="P4">
          <title>High CIWAar Flumazenil/Gabapentin</title>
          <description>2 mg flumazenil given over 20 minutes on Day 1 and Day 2. Gabapentin 300 mg Day 1; gabapentin 600 mg Day 2; gabapentin 900 mg Day 3; gabapentin 1200 mg Day 4 to 30; gabapentin 900 mg day 31-33; gabapentin 600 mg day 34-36; gabapentin 300 mg day 37-39.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low CIWAar Placebo</title>
        </group>
        <group group_id="B2">
          <title>Low CIWAar Flumazenil/Gabapentin</title>
        </group>
        <group group_id="B3">
          <title>High CIWAar Placebo</title>
        </group>
        <group group_id="B4">
          <title>High CIWAar Flumazenil/Gabapentin</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.2" spread="11.2"/>
                    <measurement group_id="B2" value="44.1" spread="11.9"/>
                    <measurement group_id="B3" value="50.3" spread="8.5"/>
                    <measurement group_id="B4" value="46.7" spread="5.6"/>
                    <measurement group_id="B5" value="46.1" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Subjects Completely Abstinent</title>
        <description>percent of subects completely abstinent during the study</description>
        <time_frame>16 week trial</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low CIWA Flumazenil/Gabapentin</title>
            <description>2 mg flumazenil given over 20 minutes on Day 1 and Day 2. Gabapentin 300 mg Day 1; gabapentin 600 mg Day 2; gabapentin 900 mg Day 3; gabapentin 1200 mg Day 4 to 30; gabapentin 900 mg day 31-33; gabapentin 600 mg day 34-36; gabapentin 300 mg day 37-39.</description>
          </group>
          <group group_id="O2">
            <title>Low CIWAar Placebo</title>
            <description>20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.</description>
          </group>
          <group group_id="O3">
            <title>High CIWAar Placebo</title>
            <description>20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.</description>
          </group>
          <group group_id="O4">
            <title>High CIWAar Flumazenil/Gabapentin</title>
            <description>2 mg flumazenil given over 20 minutes on Day 1 and Day 2. Gabapentin 300 mg Day 1; gabapentin 600 mg Day 2; gabapentin 900 mg Day 3; gabapentin 1200 mg Day 4 to 30; gabapentin 900 mg day 31-33; gabapentin 600 mg day 34-36; gabapentin 300 mg day 37-39.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Subjects Completely Abstinent</title>
          <description>percent of subects completely abstinent during the study</description>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Alcohol Withdrawal Scores (CIWAar)</title>
        <time_frame>Day 1 Day 2 Week 1</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Days Abstinent</title>
        <description>percent days abstinent during treatment</description>
        <time_frame>Weeks 1 to 6, 10 and 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low CIWA Flumazenil/Gabapentin</title>
            <description>2 mg flumazenil given over 20 minutes on Day 1 and Day 2. Gabapentin 300 mg Day 1; gabapentin 600 mg Day 2; gabapentin 900 mg Day 3; gabapentin 1200 mg Day 4 to 30; gabapentin 900 mg day 31-33; gabapentin 600 mg day 34-36; gabapentin 300 mg day 37-39.</description>
          </group>
          <group group_id="O2">
            <title>Low CIWAar Placebo</title>
            <description>20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.</description>
          </group>
          <group group_id="O3">
            <title>High CIWAar Placebo</title>
            <description>20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.</description>
          </group>
          <group group_id="O4">
            <title>High CIWAar Flumazenil/Gabapentin</title>
            <description>2 mg flumazenil given over 20 minutes on Day 1 and Day 2. Gabapentin 300 mg Day 1; gabapentin 600 mg Day 2; gabapentin 900 mg Day 3; gabapentin 1200 mg Day 4 to 30; gabapentin 900 mg day 31-33; gabapentin 600 mg day 34-36; gabapentin 300 mg day 37-39.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Days Abstinent</title>
          <description>percent days abstinent during treatment</description>
          <units>percent days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8" spread="24.2"/>
                    <measurement group_id="O2" value="86.1" spread="20.7"/>
                    <measurement group_id="O3" value="75.9" spread="27"/>
                    <measurement group_id="O4" value="95.9" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep</title>
        <time_frame>Weeks 1 to 6, 10 and 14</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acoustic Startle Response</title>
        <time_frame>Day 1, Day 3, Week 1</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Regional Brain Activity on fMRI</title>
        <time_frame>Week 2</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Low CIWA Flumazenil/Gabapentin</title>
          <description>2 mg flumazenil given over 20 minutes on Day 1 and Day 2. Gabapentin 300 mg Day 1; gabapentin 600 mg Day 2; gabapentin 900 mg Day 3; gabapentin 1200 mg Day 4 to 30; gabapentin 900 mg day 31-33; gabapentin 600 mg day 34-36; gabapentin 300 mg day 37-39.</description>
        </group>
        <group group_id="E2">
          <title>Low CIWAar Placebo</title>
          <description>20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.</description>
        </group>
        <group group_id="E3">
          <title>High CIWAar Placebo</title>
          <description>20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.</description>
        </group>
        <group group_id="E4">
          <title>High CIWAar Flumazenil/Gabapentin</title>
          <description>2 mg flumazenil given over 20 minutes on Day 1 and Day 2. Gabapentin 300 mg Day 1; gabapentin 600 mg Day 2; gabapentin 900 mg Day 3; gabapentin 1200 mg Day 4 to 30; gabapentin 900 mg day 31-33; gabapentin 600 mg day 34-36; gabapentin 300 mg day 37-39.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Raymond F. Anton, M.D.</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-1226</phone>
      <email>antonr@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

